Riudavets M., Auclin E., Mosteiro M., Dempsey N., Majem M., Lobefaro R., López-Castro R., Bosch-Barrera J., Pilotto S., Escalera E., Tagliamento M., Mosquera J., Zalcman G., Aboubakar-Nana F., Ponce S., Dal Maso A., Spotti M., Mielgo-Rubio X., Mussat E., Reyes R., Benítez J.-C., Lupinacci L., Duchemann B., De Giglio A., Blaquier J., Audigier-Valette C., Scheffler M., Nadal E., Lopes G., Signorelli D., Garcia-Campelo R., Menis J., Bluthgen V., Campayo M., Recondo G., Besse B., Planchard D., Mezquita L.. Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. EUROPEAN JOURNAL OF CANCER. 2022; 167DOI:10.1016/j.ejca.2022.02.014. PMID:35307254. IF:8.400(Q1/2D).

Bernabé-Caro R., Garrido P., García-Campelo R., Palmero R., Artal Á., Bayona C., Rodríguez-Abreu D., López-Brea M., Paredes A., Vicente D., Torres J.M.S., Majem M., Diz P., Gordo R., Coca M., de Castro J.. Alectinib after failure to crizotinib in patients with ALK-positive non-small cell lung cancer: results from the Spanish early access program. Oncotarget. 2022; 13(1)DOI:10.18632/oncotarget.28244. PMID:. IF:(Q/D).

Casali P.G., Blay J.Y., Abecassis N., Bajpai J., Bauer S., Biagini R., Bielack S., Bonvalot S., Boukovinas I., Bovee J.V.M.G., Boye K., Brodowicz T., Buonadonna A., De Álava E., Dei Tos A.P., Del Muro X.G., Dufresne A., Eriksson M., Fedenko A., Ferraresi V., Ferrari A., Frezza A.M., Gasperoni S., Gelderblom H., Gouin F., Grignani G., Haas R., Hassan A.B., Hindi N., Hohenberger P., Joensuu H., Jones R.L., Jungels C., Jutte P., Kasper B., Kawai A., Kopeckova K., Krákorová D.A., Le Cesne A., Le Grange F., Legius E., Leithner A., Lopez-Pousa A., Martin-Broto J., Merimsky O., Messiou C., Miah A.B., Mir O., Montemurro M., Morosi C., Palmerini E., Pantaleo M.A., Piana R., Piperno-Neumann S., Reichardt P., Rutkowski P., Safwat A.A., Sangalli C., Sbaraglia M., Scheipl S., Schöffski P., Sleijfer S., Strauss D., Strauss S.J., Hall K.S., Trama A., Unk M., van de Sande M.A.J., van der Graaf W.T.A., van Houdt W.J., Frebourg T., Gronchi A., Stacchiotti S., EURACAN and GENTURIS. Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up ?. ANNALS OF ONCOLOGY. 2022; 33(1)DOI:10.1016/j.annonc.2021.09.005. PMID:34560242. IF:50.500(Q1/1D).

Peters S., Pujol J.-L., Dafni U., Dómine M., Popat S., Reck M., Andrade J., Becker A., Moro-Sibilot D., Curioni-Fontecedro A., Molinier O., Nackaerts K., Insa Mollá A., Gervais R., López Vivanco G., Madelaine J., Mazieres J., Faehling M., Griesinger F., Majem M., González Larriba J.L., Provencio Pulla M., Vervita K., Roschitzki-Voser H., Ruepp B., Mitchell P., Stahel R.A., Le Pechoux C., De Ruysscher D., Stahel R., Hiltbrunner A., Pardo-Contreras M., Gasca-Ruchti A., Giacomelli N., Kammler R., Marti N., Pfister R., Piguet A.C., Roux S., Troesch S., Schneider M., Schweri R., Zigomo I., Tsourti Z., Zygoura P., Tsouprou S., Kassapian M., Dimopoulou G., Andriakopoulou C., Morin F., Amour E., Mariaule G., Archirel N., Fernandez M., Pereira E., Benito L., Lopez K., Hernández A., Chinchen S., Jurkovic H., Livingstone A., Mitchell J., Walker M., Ng S., Steer C., Briscoe K., Saqib A., Abdi E., Houghton B., O'Byrne K., Chittajallu B.R., Hughes B.G., Black A., Werner H., Zalcman G., Vaylet F., Merle P., Monnet I., Girard N., Souquet P.-J., Barlesi F., Debieuvre D., Senellart H., Poudenx M., Dixmier A., Pouessel D., Cadranel J., Lena H., Quoix E., Friard S., Audigier-Valette C., Pichon E., Kokowski K., Kirchen H., Tufman A., De-Colle C., de Langen J., Insa A., Massutí B., Pulla M.P., Aix S.P., Villanueva N., Vivanco G.L., Franks K., Califano R.. Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. ANNALS OF ONCOLOGY. 2022; 33(1)DOI:10.1016/j.annonc.2021.09.011. PMID:34562610. IF:50.500(Q1/1D).

Riudavets, M, Bosch-Barrera, J, Cabezon-Gutierrez, L, Tain, PD, Hernandez, A, Alonso, M, Blanco, R, Galvez, E, Insa, A, Mielgo, X, Moran, T, Ponce, S, Roa, D, Sanchez, JM, Majem, M. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma. Clinical & Translational Oncology. 2021; 23(12)DOI:10.1007/s12094-021-02661-2. PMID:34292495. IF:3.340(Q3/7D).

Martinez-Trufero, J, Jurado, JC, Gomez-Mateo, MC, Bernabeu, D, Floria, LJ, Lavernia, J, Sebio, A, del Muro, XG, Alvarez, R, Correa, R, Hernandez-Leon, CN, Marquina, G, Hindi, N, Redondo, A, Martinez, V, Asencio, JM, Mata, C, Morales, CMV, Martin-Broto, J. Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations for diagnosis and treatment. Spanish group for Sarcoma research (GEIS - GROUP). Part I. CANCER TREATMENT REVIEWS. 2021; 99DOI:10.1016/j.ctrv.2021.102259. PMID:34311246. IF:13.608(Q1/1D).

Martinez-Trufero, J, Jurado, JC, Hernandez-Leon, CN, Correa, R, Asencio, JM, Bernabeu, D, Alvarez, R, Hindi, N, Mata, C, Marquina, G, Martinez, V, Redondo, A, Floria, LJ, Gomez-Mateo, MC, Lavernia, J, Sebio, A, del Muro, XG, Martin-Broto, J, Valverde-Morales, C. Uncommon and peculiar soft tissue sarcomas: Multidisciplinary review and practical recommendations. Spanish Group for Sarcoma research (GEIS -GROUP). Part II. CANCER TREATMENT REVIEWS. 2021; 99DOI:10.1016/j.ctrv.2021.102260. PMID:34340159. IF:13.608(Q1/1D).

Puente, J, Pinto, A, Mendez-Vidal, MJ, del Muro, XG, Maroto, P, Vazquez, S, Luque-Caro, R, Anido, U, Strunz-McKendry, T, Upadhyay, A, Montes, J, Nuñez, AO, Portela, JG, Castellano, D. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain. Clinical & Translational Oncology. 2025; 27(5)DOI:10.1007/s12094-024-03734-8. PMID:39365365. IF:2.500(Q3/6D).